Peutz-Jeghers Syndrome (PJS) is a rare genetic disorder that is characterized by the presence of polyps in the gastrointestinal tract and dark spots on the skin. While the exact cause of PJS is unknown, research has suggested that it is caused by a genetic mutation. This article will explore the link between genetics and PJS, discussing the genetic mutation that is believed to cause the disorder, and the implications of this mutation for diagnosis and treatment.
Peutz-Jeghers Syndrome (PJS) is a rare genetic disorder that is characterized by the presence of polyps in the gastrointestinal tract and dark spots on the skin. The polyps are benign, meaning they are not cancerous, but they can cause problems with digestion and can lead to bleeding or blockages in the intestines. The dark spots are called “lentigines” and are caused by an increased number of melanocytes, the cells that produce pigment in the skin. PJS is usually diagnosed in childhood, but it can also be diagnosed in adulthood. The disorder is caused by a mutation in the STK11 gene, which is responsible for controlling cell growth. People with PJS have an increased risk of developing certain types of cancer, including colorectal, pancreatic, and gastric cancer.
The exact cause of PJS is unknown, but research has suggested that it is caused by a genetic mutation. The mutation occurs in the STK11 gene, which is responsible for controlling cell growth. People with PJS have an increased number of polyps in the gastrointestinal tract, as well as dark spots on the skin. The STK11 gene mutation is inherited in an autosomal dominant pattern, meaning that a person only needs one copy of the mutated gene to develop the disorder. People with PJS have a 50% chance of passing the mutated gene on to their children.
PJS can be difficult to diagnose, as the symptoms can be similar to other conditions. In order to diagnose PJS, doctors may perform genetic testing to look for the STK11 gene mutation. Additionally, doctors may perform an endoscopy or colonoscopy to look for the presence of polyps in the gastrointestinal tract. Once PJS is diagnosed, treatment typically involves monitoring the patient for any changes in the polyps or dark spots. Surgery may be recommended to remove any polyps that are causing problems. Additionally, people with PJS may be advised to undergo regular screening for certain types of cancer, as they are at an increased risk of developing these types of cancer.
Peutz-Jeghers Syndrome (PJS) is a rare genetic disorder that is caused by a mutation in the STK11 gene. This mutation is inherited in an autosomal dominant pattern, meaning that a person only needs one copy of the mutated gene to develop the disorder. PJS is characterized by the presence of polyps in the gastrointestinal tract and dark spots on the skin. Diagnosis of PJS involves genetic testing and endoscopy or colonoscopy, and treatment typically involves monitoring for changes in the polyps or dark spots, as well as regular screening for certain types of cancer.
1.
Stem Cell Selection Unneeded for SSc Transplant Therapy?
2.
Lung Transplant for Lung Cancer: Promising, in Rare Cases
3.
Rural-urban disparities seen in cervical cancer
4.
Obesity linked to subsequent neoplasms in childhood cancer survivors
5.
New policy review highlights the importance of health-related quality of life in advanced cancer
1.
Empowering Oncology with Data: Cloud Security, Real-World Evidence, and Clinical Insights
2.
Transplant Oncology and Anti-Cancer Immunosuppressants: The Evolution of a Paradigm in Cancer Care
3.
Is AI The New Radiologist For Breast MRI?
4.
Pediatric Oncology at the Cutting Edge: From Early Diagnosis to Lifesaving Therapies
5.
Bone Marrow Regeneration in Hematologic Recovery
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part VI
2.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III
4.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation